Cargando…

Using healthcare claims data to analyze the prevalence of BCR‐ABL‐positive chronic myeloid leukemia in France: A nationwide population‐based study

BACKGROUND: Data on Chronic Myeloid Leukemia (CML) prevalence are scarce. Here we provide an estimation of the prevalence of CML in France for the year 2014 using French national health insurance data. METHODS: We selected patients claiming reimbursement for tyrosine kinase inhibitors (TKI) or with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Foulon, Stéphanie, Cony‐Makhoul, Pascale, Guerci‐Bresler, Agnès, Delord, Marc, Solary, Eric, Monnereau, Alain, Bonastre, Julia, Tubert‐Bitter, Pascale
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Cancer Prevention
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558491/ https://www.ncbi.nlm.nih.gov/pubmed/31038849 http://dx.doi.org/10.1002/cam4.2200

Ejemplares similares

Major Molecular Response Achievement in CML Patients Can Be Predicted by BCR-ABL1/ABL1 or BCR-ABL1/GUS Ratio at an Earlier Time Point of Follow-Up than Currently Recommended
por: Huet, Sarah, et al.
Publicado: (2014)

Second‐ or third‐generation tyrosine kinase inhibitors in first‐line treatment of chronic myeloid leukemia in general population: Is there a real benefit?
por: Canet, Jim, et al.
Publicado: (2021)

A benefit–risk analysis of rotavirus vaccination, France, 2015
por: Lamrani, Adnane, et al.
Publicado: (2017)

Accounting for indirect protection in the benefit–risk ratio estimation of rotavirus vaccination in children under the age of 5 years, France, 2018
por: Escolano, Sylvie, et al.
Publicado: (2020)

Disparities in cancer‐related healthcare among people with intellectual disabilities: A population‐based cohort study with health insurance claims data
por: Cuypers, Maarten, et al.
Publicado: (2020)

ENOX2 NADH Oxidase: A BCR-ABL1-Dependent Cell Surface and Secreted Redox Protein in Chronic Myeloid Leukemia
por: Baykal, Seda, et al.
Publicado: (2023)

Increased risk of bone tumors after growth hormone treatment in childhood: A population‐based cohort study in France
por: Poidvin, Amélie, et al.
Publicado: (2018)

Mortality risk after cancer diagnosis in kidney transplant recipients: the limitations of analyzing hospital administration data alone
por: Jackson‐Spence, Francesca, et al.
Publicado: (2018)

BCR‐ABL enhances the prolyl isomerase activity of Pin 1 by interacting with DAPK1 in ph(+) ALL
por: Cao, Wen‐bin, et al.
Publicado: (2018)

COVID-19 and social inequalities: a complex and dynamic interaction
por: Quantin, Catherine, et al.
Publicado: (2022)

Outcome of 449 adult patients with rhabdomyosarcoma: an observational ambispective nationwide study
por: Bompas, Emmanuelle, et al.
Publicado: (2018)

Influence of major BCR-ABL1 transcript subtype on outcome in patients with chronic myeloid leukemia in chronic phase treated frontline with nilotinib
por: Genthon, Alexis, et al.
Publicado: (2020)

The Spliceosome: A New Therapeutic Target in Chronic Myeloid Leukaemia
por: Lebecque, Benjamin, et al.
Publicado: (2022)

BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro
por: Kauer, Joseph, et al.
Publicado: (2022)

Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
por: Mian, Afsar Ali, et al.
Publicado: (2012)

DNA methylation profiling reveals a pathological signature that contributes to transcriptional defects of CD34(+) CD15(−) cells in early chronic‐phase chronic myeloid leukemia
por: Maupetit‐Mehouas, Stéphanie, et al.
Publicado: (2018)

Impact of the SARS-CoV-2 Epidemic on Lung Cancer Surgery in France: A Nationwide Study
por: Pages, Pierre-Benoit, et al.
Publicado: (2021)

Abi1 gene silencing by short hairpin RNA impairs Bcr-Abl-induced cell adhesion and migration in vitro and leukemogenesis in vivo
por: Yu, Weidong, et al.
Publicado: (2008)

Targeting BCR-ABL(+) stem/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex
por: Chen, Min, et al.
Publicado: (2017)

Incidence and outcome of BCR‐ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors
por: Etienne, Gabriel, et al.
Publicado: (2019)

New adaptive lasso approaches for variable selection in automated pharmacovigilance signal detection
por: Courtois, Émeline, et al.
Publicado: (2021)

Impact of COVID-19 and lockdowns on pulmonary embolism in hospitalized patients in France: a nationwide study
por: Tankere, Pierre, et al.
Publicado: (2021)

BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene
por: Sharma, Nitesh, et al.
Publicado: (2015)

Pterostilbene downregulates BCR/ABL and induces apoptosis of T315I-mutated BCR/ABL-positive leukemic cells
por: Kawakami, Shohei, et al.
Publicado: (2022)

Instrumental variable analysis in the context of dichotomous outcome and exposure with a numerical experiment in pharmacoepidemiology
por: Koladjo, Babagnidé François, et al.
Publicado: (2018)

Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results
por: Hughes, T P, et al.
Publicado: (2017)

Late toxicity comparison of alkylating‐based maintenance regimen with cyclophosphamide (VAC) vs ifosfamide (VAI) in Ewing sarcoma survivors treated in the randomized clinical trial Euro‐EWING99‐R1 in France
por: Corvest, Victoria, et al.
Publicado: (2022)

BCR: a new target in resistance mediated by BCR/ABL-315I?
por: Haberbosch, Isabella, et al.
Publicado: (2016)

The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins
por: You, Liangshun, et al.
Publicado: (2016)

Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months
por: Casado, Luis-Felipe, et al.
Publicado: (2015)

Pharmacovigilance evaluation of the relationship between impaired glucose metabolism and BCR‐ABL inhibitor use by using an adverse drug event reporting database
por: Okada, Naoto, et al.
Publicado: (2018)

Expanding the Diversity of Allosteric Bcr-Abl Inhibitors
por: Deng, Xianming, et al.
Publicado: (2010)

An In-House Method for Molecular Monitoring of BCR-ABL
por: Sercan, Hakkı Ogün, et al.
Publicado: (2012)

Depression of oncogenecity by dephosphorylating and degrading BCR-ABL
por: Gao, Miao, et al.
Publicado: (2016)

AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells
por: Zhou, Liang L., et al.
Publicado: (2008)

The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification
por: Zeng, Dachuan, et al.
Publicado: (2022)

Gamma-aminobutyric acid, a potential tumor suppressor for small airway-derived lung adenocarcinoma
por: Schuller, Hildegard M., et al.
Publicado: (2008)

Adenovirus-delivered CIAPIN1 small interfering RNA inhibits HCC growth in vitro and in vivo
por: Li, Xiaohua, et al.
Publicado: (2008)

Alkenyl group is responsible for the disruption of microtubule network formation in human colon cancer cell line HT-29 cells
por: Hosono, Takashi, et al.
Publicado: (2008)

Effects of high-amylose maize starch and butyrylated high-amylose maize starch on azoxymethane-induced intestinal cancer in rats
por: Clarke, Julie M., et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_2336tqg82re1vvjpuurgmbucgg